Our approach to innovation

In an increasingly complex world, collaboration with companies, institutions, and research networks is more important than ever to address the challenges of Life Sciences to create effective therapeutic solutions quickly.

At Dompé, we are investing in new collaborative approaches aimed at innovation. Among our priorities is the growth of an ecosystem engaging in very different skills—from biotechnology, pharmaceutical research, supercomputing, and artificial intelligence to materials sciences—all aimed at developing the best therapeutic solutions of tomorrow.

We have been operating in this context of Open Innovation for years and now embrace a network of more than 300 entities including research centers and universities around the world, within a constantly evolving public-private scientific relationships.


Active collaborations around the world


MTA agreements signed


Collaborations initiated in the last year,
including acquisitions, clinical trials, and licensing agreements

Growth based on collaboration

At Dompé, our mission is to provide new therapies and treatments to improve people's lives. We are convinced that partnering with the best academic and industrial groups is the most effective way to accelerate the research of excellence and bring new treatments to patients who need them.

For each collaboration to be of truly mutual benefit, we offer our know-how gained from more than 130 years of history and advanced technological platforms while, at the same time, allowing autonomy and flexibility to our partners. Our collaborations are structured to enhance the qualities and specificities of all parties involved. We ensure this through relationships based on shared values ​​such as a passion for science, attention to people's needs, and the research and development of drugs for therapeutic needs.

Dompé farmaceutici S.p.A. Single shareholder company / Share capital € 50.000.000,00
REA MI 289519 - A registered company in Milan, Italy / Tax code and VAT number IT00791570153